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Objective. Systemic sclerosis-associated pulmonary arterial hypertension (SScPAH) has a disturbed function of the right ventricle
(RV) when compared to idiopathic PAH (IPAH). Systemic sclerosis may also aﬀect the heart. We hypothesize that RV diﬀerences
may occur at the level of interstitial inflammation and—fibrosis and compared inflammatory cell infiltrate and fibrosis between
the RV of SScPAH, IPAH, and healthy controls. Methods. Paraﬃn-embedded tissue samples of RV and left ventricle (LV) from
SScPAH (n = 5) and IPAH (n = 9) patients and controls (n = 4) were picrosirius red stained for detection of interstitial fibrosis,
which was quantified semiautomatically. Neutrophilic granulocytes (MPO), macrophages (CD68), and lymphocytes (CD45) were
immunohistochemically stained and only interstitial leukocytes were counted. Presence of epi- or endocardial inflammation, and
of perivascular or intimal fibrosis of coronary arteries was assessed semiquantitatively (0–3: absent to extensive). Results. RV’s of
SScPAH showed significantly more inflammatory cells than of IPAH (cells/mm2, mean ± sd MPO 11 ± 3 versus 6 ± 1; CD68
11 ± 3 versus 6 ± 1; CD45 11 ± 1 versus 5 ± 1 , P < .05) and than of controls. RV interstitial fibrosis was similar in SScPAH and
IPAH (4 ± 1 versus 5 ± 1%, P = .9), and did not diﬀer from controls (5 ± 1%, P = .8). In 4 SScPAH and 5 IPAH RV’s foci of
replacement fibrosis were found. No diﬀerences were found on epi- or endocardial inflammation or on perivascular or intimal
fibrosis of coronary arteries. Conclusion. SScPAH RVs display denser inflammatory infiltrates than IPAH, while they do not diﬀer
with respect to interstitial fibrosis. Whether increased inflammatory status is a contributor to altered RV function in SScPAH
warrants further research.
1. Introduction
Systemic sclerosis (SSc) is a disease with a multifaceted
pathology which is characterized by an enhanced inflam-
matory status, vasculopathy, and excessive fibrosis in skin
and internal organs [1]. Pulmonary involvement, either lung
fibrosis or pulmonary arterial hypertension (PAH), is the
leading cause of death in SSc [1]. SSc complicated by PAH
(SScPAH) carries a mortality of 50% at 3 years, which is
higher when compared to idiopathic PAH (IPAH) [2–4].
These diﬀerences might be explained by comorbidity due
to the systemic nature of SSc, a higher age of onset of disease,
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Table 1: General patient characteristics.
SScPAH IPAH Control
N = 5 N = 9 N = 4
Age, yrs 47± 4 47± 4 31± 4
Male/Female no. 1/4 2/7 —
Survival 1.1± 0.5 3.7± 0.9 —
Heart rate 85± 3 78± 5
mPpa, mmHg 46± 7 62± 4
PCWP, mmHg 6± 2 5± 2
PVR, dynes·s·cm−5 1221± 691 1157± 144
CI, l/min·m2 2.3± 0.9 2.3± 0.5
Systolic blood pressure 105± 2 118± 8
Diastolic blood pressure 69± 6 73± 5
TLC, % 89± 5 92± 5
DLCO, % 42± 6 64± 6
Therapy at time of death
Prostacycline (n) 4 7
ERA (n) 1 2
PDE-5 inhibitor (n) 1 0
ABS 1
Values expressed as mean ± SE or otherwise as stated. Abbreviations: ABS: atrial balloon septostomy; CI: cardiac index; DLCO%: percentage of predicted of
the diﬀusion capacity of the lung for carbon monoxide; ERA: endothelin receptor antagonist; mPpa: mean pulmonary artery pressure; PCWP: pulmonary
capillary wedge pressure; PDE-5: phosphodiesterase 5; PVR: pulmonary vascular resistance; IPAH: idiopathic pulmonary arterial hypertension; SScPAH:
systemic sclerosis-associated pulmonary arterial hypertension; TLC%: percentage of predicted total long capacity.
and diﬀerences in pulmonary vasculopathy [5, 6]. There are
also indications that the RV in SScPAH adapts diﬀerently as
compared with IPAH patients: several studies have shown
lower pulmonary arterial pressures in SScPAH than in IPAH,
while cardiac index and pulmonary vascular resistance were
similar [6–10]. Additionally, it has been demonstrated that
RV pump function is diﬀerent in SScPAH when compared
to IPAH [10]. Furthermore, a diﬀerent response to cardiac
load has been suggested by the disproportionate levels of
N-terminal probrain natriuretic peptide found in SScPAH
compared with IPAH, despite the less severe hemodynamic
abnormalities [7, 11].
There is no knowledge concerning the etiology of altered
RV function and adaptation in SScPAH. Here, for the
first time, histolopathologic characteristics of the RV in a
well-defined SScPAH group will be explored, focusing on
inflammation and fibrosis, two main pathologic features of
SSc. Comparison is made with RVs from IPAH patients
and healthy controls. It is hypothesized that inflammatory
status and fibrosis are quantitatively diﬀerent in the RV
interstitial myocardium of SScPAH patients as compared
with that of IPAH patients. To test this hypothesis, we
determined the numbers of macrophages, lymphocytes,
and neutrophilic granulocytes and quantified fibrosis in
the myocardial interstitium of RV’s of SScPAH and IPAH
patients. To evaluate an eﬀect of pressure overload from
the lesser circulation in PAH, RV interstitial fibrosis and
interstitial inflammation were compared to the left ventricle
(LV). Hearts from healthy individuals that died acutely of
traumatic causes served as controls.
2. Methods
2.1. Patient Characteristics. The cases examined in this study
were retrieved from the departments of pulmonary diseases
of the VU University Medical Center, Amsterdam, the
Netherlands. The study was approved by the Institutional
Review Board on Research Involving Human Subjects of the
VU University Medical Center.
Patients who had been treated for PAH between 1998
and 2007, of whom cardiac tissue obtained at autopsy was
available, were deemed eligible for the study. General patient
characteristics are described in Table 1. The diagnosis of SSc
(as established by a reumathologist), SScPAH, and IPAH
was verified by reviewing the medical records, including
lung function data at baseline as well as HRCT studies.
Patients with restrictive disease, as indicated by total lung
capacity as percentage of predicted (TLC%) <70%, vital
capacity (VC%) <70% and/or severe fibrosis on HRCT
scan, were classified as pulmonary hypertension due to
restrictive disease and therefore excluded from this study. SSc
classification, SSc disease duration, and antibody profile were
recorded (Table 2) [12, 13]. Of the SScPAH group, 3 patients
had died of RV failure, one had died of hypovolumic shock
due to iatrogenic intra-abdominal bleeding after ascites
drainage which was caused by right heart failure, and one
died postoperatively within 2 days after lung transplantation.
Eight IPAH patients had died of RV failure and one of
hemorrhagia from the arteria pulmonalis.
The hearts from four patients who had acutely died
from traumatic, noncardiopulmonary, noncerebral causes
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Table 2: Characteristics of SScPAH patients.
Antibody- profile Cause of death
SSc disease duration
(yr)§
Survival after PAH
diagnosis (yr)
Medication at time of
death
1 LcSSc∗ Anticentromere RV failure 4 0,5 prostacyclin
2 LcSSc Anticentromere RV failure 12 0,75 prostacyclin
3 LcSSc Anticentromere RV failure 1 0,08 prostacyclin
4 LcSSc Anticentromere
Iatrogenic abdominal bleeding
due to ascites punction
1 3 ERA, PDE-5 inhibitor
5 LcSSc ANA Post- LTX 13 0,42 Prostacyclin
Abbreviations: ANA: antinucleolar antibody; ERA: endothelin receptor antagonist; LcSSc: Limited cutaneous SSc; LTX: lung transplantation; PDE-5:
phosphodiesterase 5; RV: right ventricle; SScPAH: Systemic sclerosis-associated pulmonary arterial hypertension. ∗According to [13]. §Since first non-
Raynaud symptom, at time of diagnosis of pulmonary arterial hypertension. Ascites caused by RV failure.
and who did not have a cardiopulmonary medical history,
served as healthy controls.
2.2. Tissue Preparation and Immunohistochemistry
2.2.1. Inflammation. Serial adjacent sections of myocardial
tissue (4 μm thick) were deparaﬃnised for 10 minutes
in xylene at room temperature and dehydrated through
ascending concentrations of ethanol. Endogenous peroxidase
activity was blocked by incubation in 0.3% (v/v) H2O2 in
methanol for 30 minutes. Tissue sections were subjected
to antigen retrieval by boiling in 10 mM sodium citrate
buﬀer, pH 6.0 for 10 minutes in a microwave oven. All
antibodies and normal serum were diluted in PBS containing
1% (w/v) bovine serum albumin (BSA). Tissue sections
were preincubated for 10 minutes with normal rabbit and
normal swine serum (1 : 50), followed by incubation for 1 hr
with either polyclonal rabbit antihuman myeloperoxidase
(MPO) (Dako, A0398, Denmark, 1 : 50 dilution), or mouse
monoclonal antibody CD68 (KP1) (Dako, M0814, Denmark,
1 : 400 dilution) and mouse monoclonal anti-human CD45
(Dako, M0701, Denmark, 1 : 50 dilution) antibodies. After
washing in PBS, tissue slides were incubated for 30 minutes
with a biotin-conjugated secondary antibody rabbit anti-
mouse biotin (1 : 500 dilutions) and swine anti-rabbit biotin
(1 : 300 dilution) (Dako, A0063, Denmark), followed again
by washing in PBS. Then, slides were incubated with
streptavidin-biotin complex (sABC; 1 : 1000 dilutions) for 1
hour. Finally, primary antibodies were visualized with 3,3′-
diaminobenzidine (DAB; 0.1 mg/ml, 0.02% H2O2). Slides
were counterstained with hematoxylin and mounted with
Depex and a coverslip.
As a negative control, the primary antibody was replaced
by phosphate-buﬀered saline or an irrelevant antibody; these
heart tissue slides were found to be negative.
2.2.2. Fibrosis. In order to determine the amount of intersti-
tial fibrosis, paraﬃn-embedded sections of myocardial tissue
(4 μm thick) were stained with Picrosiriu-red. Sections were
incubated for 10 minutes in xylene at room temperature to
remove paraﬃn and transferred to water through descending
concentrations of ethanol (100%, 96%, 80%, and 70%, all
10 s). Staining was performed using 0.1% solution of Sirius
red F3BA in saturated aqueous solution of picric acid for one
hour at 25◦C [14, 15]. Subsequently, sections were diﬀerenti-
ated in 0.01N HCl for 2 minutes. Sections were dehydrated
in ascending concentrations of ethanol (70%, 80%, 96%,
and 100%, each 10 seconds) and cleared in two stages in
xylene, 10 minutes each. Sections were covered with Entellan
mounting medium (Merck, Darmstadt, Germany) and a
glass cover slip. In addition, to determine the presence of
intimal fibrosis in coronary arteries and arterioles, adjacent
sections were stained for Elastica von Gieson (EvG).
2.3. Morphometric Analyses
2.3.1. Inflammatory Cells. In each tissue slide of the
RV and LV, intramyocardial areas were randomly cho-
sen, with a minimum area of 15 mm2. In these areas,
the number of extravascular neutrophilic granulocytes
(MPO+), macrophages/histiocytes (CD68+) and lympho-
cytes (CD45+) was counted (Figure 2). Intravascular inflam-
matory cells were excluded. The average number of intramy-
ocardial, extravascular inflammatory cells per mm2 was then
calculated as the total score for each specimen according to
Begieneman et al. [16]. All cell counts and scorings were
done by two investigators (MJO, KTBM) who were blinded
to the clinical diagnosis. In order to minimize interobserver
variability, both investigators counted a training set of 9
diﬀerent histological samples (3 of each staining). The inter-
observer variation was <10% with a correlation of r2 = 0.98.
The presence of perivascular infiltrates and inflammatory
infiltration of the endocardium and the epicardium was
scored on a 4 point scale, ranging from 0 (absent) to 3
(extensive).
2.3.2. Fibrosis. Picrosirius-red stained sections of paraﬃn-
embedded cardiac biopsies were scanned in total with Mirax
scan system (Zeiss, AG Germany). Areas were randomly
selected from the digitised slides at a 20x magnification,
covering at least 15% of the total area (Figure 1). Care
was taken not to include vessels into the selected areas to
ensure only interstitial myocardial fibrosis was quantified.
Interstitial myocardial fibrosis was assessed in the RV and
LV, using a fully automated analysis according to Mouchaers
[17].
In addition, the entire sections were, semiquantitatively,
investigated for epicardial and endocardial fibrosis and
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Figure 1: Sections of myocardial tissue stained with antibodies against (a) neutrophilic granulocytes (MPO positive), (b) macrophages
(CD68 positive), or (c) lymphocytes (CD45 positive). Arrows indicate positive cells.
scored on a 4 point scale ranging from 0 (absent) to 3
(extensive). Likewise, EvG-stained sections were used to
score the presence of replacement fibrosis, as defined by
fibrotic areas within the myocardium coincident with a loss
of cardiomyocytes as well as for perivascular and intima
fibrosis of coronary arteries/arterioles.
2.4. Statistical Analysis. For the quantification of interstitial
fibrosis and interstitial inflammatory cells, 5 samples of
myocardial tissue from the RV and 4 from the LV of SScPAH
patients were analyzed; 9 samples were available of both
the RV and LV from IPAH patients and 4 samples from
controls. Mann-Whitney U was used to determine diﬀer-
ences between groups. All histochemical data are presented
in graphs as median (range) and patient characteristics in
tables as mean ± SEM. Fisher’s exact test was used for
comparison of infiltration of inflammatory cells of the endo-
and epicardium between groups. P < .05 was considered
statistically significant.
3. Results
3.1. Patient Characteristics and Haemodynamics. Patient
characteristics are listed in Tables 1 and 2. SScPAH and IPAH
groups did not diﬀer with respect to mean age. Mean survival
of the SScPAH patients was significantly shorter compared to
IPAH patients. Haemodynamic parameters at diagnosis were
not diﬀerent between the groups. However, SScPAH patients
tended to have a lower mean pulmonary artery pressure as
compared with the IPAH patients. DLCO in the SScPAH
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Figure 2: The number of (a) myeloperoxidase positive cells, (b) CD68 positive cells, and (c) CD45 positive cells was determined in the RV
and the LV of systemic sclerosis-associated pulmonary arterial hypertension (SScPAH), idiopathic pulmonary arterial hypertension (IPAH)
patients and in control subjects. Median and range are shown.
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Figure 3: Representative samples of picrosirius red-stained myocardial sections of the RV of SScPAH and IPAH patients, used for
quantification of interstitial fibrosis. Arrows indicate the red-coloured strains of fibrosis.
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Figure 4: Quantification of picrosirius red staining in the RV of SScPAH, IPAH, and control subjects in (a) the RV and (b) the LV. Median
and range are shown.
group was significantly lower as compared with the IPAH
group. Two patients in the SScPAH group and 4 in the IPAH
group had been treated with aldosteron antagonists or ACE-
inhibitors. None of the patients had systemic hypertension.
3.2. Inflammation. The RV’s of SScPAH showed significantly
more interstitial MPO- and CD45-positive cells when com-
pared to IPAH. The numbers of MPO-, CD68- and CD45-
positive cells/area were also increased when the SScPAH
RV’s were compared to normal controls (Figures 2(a), 2(b),
and 2(c), and examples of immunohistochemical stainings
are shown in Figure 1). In the RV of IPAH versus normal
controls, no significant diﬀerences observed. In the LVs of
SScPAH and IPAH, there were no significant diﬀerences in
the number of inflammatory cells either. In SScPAH LV’s,
significantly more CD45 positive cells were observed as
compared to normal controls, but no such diﬀerences were
found for MPO nor for CD68. IPAH LV’s demonstrated
significantly more CD68 and CD45 as compared with
normal controls.
Infiltration of the endocardium and epicardium was not
diﬀerent between the SScPAH and IPAH, nor between RV or
LV, for neither cell type (not shown). In all ventricles, a mild
perivascular infiltration was observed, but no transmural
infiltration of the vessel wall suggestive of vasculitis.
3.3. Fibrosis. Representative samples of picrosirius red-
stained sections, used for quantification of interstitial fibro-
sis, are depicted in Figure 3. Interstitial fibrosis in the RV
was not diﬀerent between the SScPAH and IPAH groups
(Figure 4). LV interstitial fibrosis did not diﬀer between the
three diﬀerent groups either. Focal epi- and endocardial
fibrosis was seen in all subjects.
On EvG-stained sections we analysed putative foci of
replacement fibrosis. This was observed in 4 out of 5 RV’s
from SScPAH patients and in 5 out of 8 RV’s from IPAH
patients. The LV demonstrated replacement fibrosis in 2 out
of 4 SScPAH patients and 5 out of 8 IPAH patients. In most
cases, this fibrosis was patchy, showing microscopic foci,
mostly localised subendocardially (Figure 5(a)). In few cases,
a pattern of perivascular fibrosis of the microvasculature
was observed, radiating from the epicardial coronary arteries
to the subendocardial myocardium, ending in microscopic
fibrotic foci (Figure 5(b)). In some cases, small infarcts
(observed at gross pathology) were observed (1 SScPAH RV,
2 SScPAH LVs, and 2 IPAH RVs) (Figure 5(c)). This was not
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Figure 5: Representative samples of Elastica von Gieson stained myocardial sections of the RV of SScPAH patients, used for studying fibrosis
in detail. (a) Some RV’s of SScPAH patients revealed a pattern patchy replacement fibrosis, mostly localized subendocardially. This was
also seen in some hearts of IPAH patients, but not observed in control. (b) In few cases, a pattern of strands of collagenous fibrous tissue
surrounding microvasculature was observed, radiating from the epicardial coronary arteries to the subendocardial myocardium. (c) In some
cases small infarcts in both SSc and IPAH hearts were observed. (d) An increase in perivascular fibrosis in some SScPAH hearts and in 1
IPAH heart was observed. All these observations were not made in control hearts.
observed in hearts of control subjects. Finally, we investigated
the occurrence of intimal fibrosis in intramyocardial coro-
nary arteries and arterioles. This was observed in SScPAH in
1 RV and 3 LVs and IPAH in 1 RV. Perivascular fibrosis and
adventitial remodeling was equally observed in both SScPAH
and IPAH right and left ventricles (Figure 5(d)). This was not
diﬀerent from controls.
4. Discussion
In this paper, for the first time, histopathologic features
of fibrosis and inflammatory status are described in the
interstitial myocardium of the RV in a well-documented
SScPAH group. As RV’s of SScPAH patients have worse
function than IPAH RV’s, comparison took place with
IPAH RV’s. We observed significantly more extravascular
inflammatory cells in the myocardial interstitium of the
RV of SScPAH as compared with the RV of IPAH and as
compared with normal controls. No significant diﬀerence
in this respect was found between IPAH RV’s and control
RV’s, nor between the LV’s of both PAH disease groups.
Interstitial myocardial fibrosis in the RV did not significantly
diﬀer between SScPAH and IPAH, nor between the PAH
disease groups and normal controls. No diﬀerences were
found with respect to interstitial fibrosis for the LV either.
Although PAH patients had more replacement, perivascular,
and subendocardial fibrosis when compared to controls, no
diﬀerences were found between SScPAH and IPAH patients.
The presence of inflammatory cells in (interstitial)
myocardial tissue in SScPAH has not been described pre-
viously. Two SSc cases with clinical LV failure, but with-
out signs of increased RV afterload, have been described,
demonstrating an increase in T-cells and CD68 positive
cells in endomyocardial biopsies of the RV. [18] In IPAH,
interstitial inflammatory cell infiltration in the RV did not
diﬀer significantly from normal controls in a previous report
[16], which is in agreement with the present findings.
Fibrosis in hearts of SSc patients has been shown in
autopsy studies, and tended to be patchy and distributed
throughout all levels of the myocardium of the RV and
LV [19–23]. In endomyocardial biopsies of RV’s of SSc
patients, Fernandes et al. [24] found increased collagen
deposition as compared with normal controls. None of the
above described studies included patients with confirmed
pulmonary (arterial) hypertension. A recent study on cardiac
MRI features in 52 SSc patients described delayed contrast
enhancement, indicating the presence of myocardial fibrosis,
in 1 of 8 SScPAH patients [25]. In IPAH, fibrosis in
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endomyocardial biopsies of the RV has been reported to be
“mildly” increased, however, quantification nor specification
concerning location was reported [26].
The study is limited by the small sample size. Despite
this, the examined SScPAH RV histology is unique and
has not been subject of study previously, set apart from
the SSc group as a whole. Special care was taken to
include only cases in which both the diagnosis of SSc
and PAH was unequivocal, so as to optimize homogeneity,
and thereby optimize statistical power. We therefore think
that the exploratory data presented here provide relevant
insight, warranting further study. An inherent limitation of
this study is the use of archival autopsy material, which
is shared by previous studies on this topic. As practically
all patients died of PAH-related causes, the pathology in
this series represents end-stage disease. Consequently, its
features might diﬀer from earlier and subclinical phases of
the same disease. Also, sampling and processing of the RV
and LV is often not done in a standardized way over the
years. As little is known about uneven distribution of either
fibrosis or inflammation, it is unknown as to whether this
is a limitation to the study. For the immunohistochemical
stainings, an internal positive control was present in all
slides, and staining intensity as a possible consequence of
diﬀerences in processing was irrelevant. The observation that
even in end-stage disease significant diﬀerences were found
in inflammatory cells suggests at least diﬀerent pathogenic
pathways. Our measurements included all intramyocardial
areas (such as subepicardium, endocardium, or midwall
area), and therefore the results depict the overall amount
of interstitial fibrosis within the myocardium. Additionally,
global scanning of the samples did not reveal diﬀerences
between midwall and subepi-endocardial areas. This issue
might be relevant as studies on cardiac MRI with delayed
contrast enhancement suggest the mid-wall area as the
predilection area in the majority of SSc patients who
demonstrated DCE [25, 27, 28]. However, these studies
did not describe DCE-uptake in the RV and results could
not be histologically confirmed. One patient died within 2
days after lung transplantation. The short-term eﬀects on
RV of a sudden afterload normalization at histopathologic
level are not known. It is known that the RV undergoes
significant RV-remodelling within 3 to 6 months after lung
transplantation as demonstrated by MRI [29]. We do not
think that the RV in this patient morphologically underwent
major changes.
How do we interpret the elevated numbers of interstitial
inflammatory cells in the RV of SScPAH hearts compared
to IPAH? Mechanical stress due to RV pressure overload
could be responsible for this finding as such a diﬀerence
was not found when the LV’s of both disease groups
were compared. Indeed, increased mechanical stress may
induce cytokine expression (e.g., monocyte chemoattractant
protein-1 (MCP) and interleukin (IL)-8) in several cell types
such as endothelial cells and cardiomyocytes [30, 31] through
production of reactive oxygen species (ROS) with secondary
activation of NF-κB [32].
Increased susceptibility to ischemia, a known trigger to
induce inflammatory cytokines, might also explain increased
inflammatory cell infiltration in SScPAH, as structural and
functional abnormalities of the small coronary arteries are
known features of SSc [33–37]. However, in the present
study we did not find diﬀerences in the presence of arteriolar
intimal fibrosis between SScPAH and IPAH RV’s.
It is unclear whether the inflammatory cells are innocent
bystanders or whether they play an active role in altered RV
function in SScPAH. Most links between inflammation and
a reduced contractility in chronic heart diseases have been
forged on the basis of cytokines and chemokines [38–43] but
there are limited data on the eﬀect of cardiac tissue injury by
neutrophils. In addition, it is known that macrophages can
directly impair contractility of individual cardiomyocytes
[44–48].
A significantly higher CD45-positive cell infiltration was
found in the LV’s of both SScPAH and IPAH as compared
with controls, which is diﬃcult to to explain. Increased CD45
infiltration of the myocardium is seen in viral myocarditis
[49], however, in none of the patients other signs of
myocarditis, such as necrosis or degradation of myocytes
along with lymphocytic infiltrates, was seen.
We found no quantitative diﬀerences of interstitial
fibrosis between SScPAH and IPAH. This, however, does not
exclude the possibility that the composition or structure of
the extracellular matrix components is diﬀerent in SScPAH,
which may result in diﬀerent eﬀects on ventricular function
[47, 50, 51]. In agreement with previous reports, we did
observe patchy and moderate replacement fibrosis in several
hearts of SScPAH patients, both in the RV and LV [22, 52–
54]. Replacement fibrosis is the end-result of either inflam-
mation mediated and/or ischemia-mediated damage [55]. It
is not clear in this study which mechanism predominates in
SScPAH. As replacement fibrosis was also observed in IPAH
patients, but not in control hearts, the focal fibrosis may
ultimately be the result of increased RV pressure overload in
pulmonary hypertension, regardless of its cause.
In conclusion, the present paper shows an increased
number of inflammatory cells in the RV myocardial intersti-
tium in SScPAH as compared with IPAH. No diﬀerences in
(interstitial) fibrosis between the groups were found. Further
research is warranted to evaluate the significance of these
findings for the RV function in SScPAH patients.
Key Messages
(1) RV’s of SScPAH patients show more interstitial
inflammatory cells than RV’s of IPAH patients.
(2) No quantitative diﬀerences in interstitial fibrosis were
found between SScPAH RV’s and IPAH RV’s.
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